# The Safety and Effectiveness of Intravenous Anidulafungin as a Treatment for Patients With Invasive Candidiasis.

> **NCT00037219** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 120 (actual)

## Conditions studied

- Candidiasis

## Interventions

- **DRUG:** Anidulafungin, VER002

## Key facts

- **NCT ID:** NCT00037219
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-08
- **Primary completion:** —
- **Final completion:** 2002-11
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2008-10-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00037219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00037219, "The Safety and Effectiveness of Intravenous Anidulafungin as a Treatment for Patients With Invasive Candidiasis.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00037219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*